翰森制药(03692.HK)阿美乐第四项适应症获发药品注册证书

阿斯达克财经
09 May

翰森制药(03692.HK) 公布,创新药阿美乐获国家药品监督管理局签发的药品注册证书,批准增加“用于II-IIIB期具有表皮生长因子受体外显子19缺失或外显子21(L858R)置换突变的成人非小细胞肺癌患者的治疗,患者须既往接受过手术切除治疗,并由医生决定接受或不接受辅助化疗”适应症。此为阿美乐获批的第四项适应症。

阿美乐是中国首个原研三代EGFR-TKI创新药,此前已于中国获批三项适应症。(ha/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-05-09 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10